**Society for Clinical Research Sites** **MySCRS.org**
**Central & Eastern European Ambassador Symposium**
**Warsaw, Poland**
**18 November 2019**

| Time | SCRS Ambassador Symposium Session | Speakers |
|---|---|---|
| 8:30 - 9:30 | **Registration** | |
| 9:30 - 9:40 | **Welcome & Opening Remarks** | **Wojciech Szczepanik**, SCRS Ambassador |
| 9:40 - 10:10 | **SCRS & the Site Landscape**<br>The Society for Clinical Research Sites (SCRS) represents the global clinical research site community with the mission to unify the voice of the global clinical research site community for greater site sustainability. Join this session to gain insight into operations and metrics to position your site for success. | **Dan Milam**, Vice President, Global Engagement, **SCRS** |
| 10:10 - 10:40 | **Survey Says: Global Challenges in Site Grant Payments**<br>Hot off the press! SCRS and Greenphire recently completed a survey asking sites around the world about the challenges with their invoicing process. In this session, we will discuss how much time and effort sites are spending generating and reconciling invoices and other resource-intensive tasks that could be better spent on actual clinical research. Opportunities for process improvement including sponsor-site communications and technology enhancements will also be highlighted. | **Kyle Cunningham**, Chief Product Officer, **Greenphire** |
| 10:40 - 11:00 | **Changes in Clinical Trial Regulations**<br>What are the crucial objectives of new clinical trials regulations? Will the changes foster innovation and make the European market more attractive? Can we expect the rights, safety and well-being of subjects and the reliability and robustness of the data generated in the clinical trial to be better protected? This session will provide an analysis of the latest regulatory initiatives in EMEA (536/2014) impacting clinical trials today. | **Aneta Sitarska-Haber**, Senior Clinical Manager, **PPD** |
| 11:00 -11:15 | **Networking Break** | |
| 11:15 - 11:45 | **How Sites May Benefit from the MRA Activity & Implementation of the European Clinical Research Infrastructure Network (ECRIN) Strategies**<br>The development of medical and health sciences and contribution to the growth and innovation of Polish medicine are the most important goals that have been set before the newly established Medical Research Agency, whose main role will be to provide funding for analyses and clinical trials in healthcare. Join this session to learn how sites stand to benefit from these activities and strategies. | **Anna Bajera, Medical Research Agency** |
| 11:45 - 12:35 | **Panel Discussion: Opportunities & Risks for Europe Joining the European Clinical Research Infrastructure Network (ECRIN)** | **Vivienne van de Walle, MD, PhD, CPI**, Director & Owner, **PT&R** (The Netherlands) - Facilitator<br>**Michaela Vancova**, Clinical Operations Director, **Slovak Research Center** (Slovakia)<br>**Lucie Špatenková**, Managing Director, **Clinical Research Center** (Czech Republic)<br>**Anna Bajera, Medical Research Agency** (Poland)<br>**Aneta Sitarska-Haber,** Senior Clinical Manager, **PPD** (Poland) |
| 12:35 - 13:35 | **Lunch** | |
| 13:35 - 14:05 | **Site Readiness to Perform Clinical Trials in Hematology & Oncology**<br>50% of all clinical trials are in hematology and oncology. Sites that want to access this wealth of opportunity will need to familiarize themselves with the inherent challenges and logistical and regulatory considerations specific to the field. This session will focus on the fundamentals of these therapeutic areas and how to prepare your site to engage in hematology and oncology clinical trials. | **Radosław Jadczak, MD MBA**, Therapeutic Strategy Director, Oncology, **IQVIA** |
| 14:05 - 14:55 | **Panel Discussion: Requirements Clinical Trials in Hematology & Oncology** | **Michaela Vancova**, Clinical Operations Director, **Slovak Research Center** (Slovakia) - Facilitator<br>**Anna Sawiec, MD**, Head of the Clinical Research Center / Department of Oncological and Hematooncological Trials, **Pratia MCM Kraków** (Poland)<br>**Radosław Jadczak, MD MBA**, Therapeutic Strategy Director, Oncology, **IQVIA** (Poland)<br>**Roman Fishchuk**, Head of Clinical Trials Department, **Ivano-Frankivsk Central City Clinical Hospital** (Ukraine)<br>**David Rosenbaum**, Consultant, **Rosenbaum Consulting** (Bulgaria) |
| 14:55 - 15:10 | **Networking Break** | |
| 15:10 - 16:00 | **Become the Site of Choice for Sponsors & CROs**<br>Secure your site's future by becoming familiar with the criteria sponsors and CROs evaluate when selecting their sites of choice, and how involvement in different formats like site alliances, site networks and more impact your chances of selection. | **Małgorzata Gerjatowicz-Osmańska**, MBA, Site Director, **Pratia** (Poland) - Facilitator<br>**Dorota Kawa-Sokołowska**, Director, Clinical Site Operations - Poland & Baltic Countries, **Pfizer** (Poland)<br>**Edward Czerwiński**, Professor and Director, **Krakow Medical Centre** (Poland)<br>**Hristiyan Kosturski, MD, Owner, SMO Bulgaria** (Bulgaria)<br>**Wojciech Kaczmarski**, Country Head Poland, **Roche** (Poland) |
| 16:00 - 16:30 | **Decentralized Clinical Trials as a Patient Recruitment Solution**<br>Patient recruitment and retention are some of the most challenging aspects of clinical trials. With optimal use of local healthcare infrastructure supported by novel technologies, Decentralized Clinical Trials (DCTs) offer a promising solution for faster trial participant recruitment, improved retention, shorten clinical trial timelines, accelerated patient access to new treatments and reduced costs for sponsors. | **Janusz Kabata, MD, PhD, MBA**, CEO, **GP4research** |
| 16:30 - 17:00 | **Clinical Trial Trends in Central & Eastern Europe**<br>Is Central and Eastern Europe (CEE) gaining or losing market share in the clinical trials industry? Which countries and regions are leading globally? Can the reputation of a country be measured? Are the leading sponsors in CEE the same as those globally? What is the average number of sites per trial in CEE, and how is this benchmarked against other markets? This session will answer these questions and more as we uncover recent geographic trends in global clinical trials and learn how CEE is fairing against stiff global competition. | **Vladimir Misik, PhD**, Founder & Managing Partner, **LongTaal** |
| 17:00 - 17:30 | **Social Media: Addressing Patient Communication Opportunities & Challenges**<br>Patient recruitment and retention and patient access to clinical trial information are top challenges in clinical trials. Most experts agree that social media provides a solution, but it can be difficult to identify which tactics and platforms are best-suited for your organization. This session will help you evaluate available social media platforms and determine which tactics will best align your organization for success in accessing, recruiting and retaining clinical trial patients. | **Piotr Sawicki**, Head of Clinical Trials Department, **Medical Center CMP** |
| 17:30 | **Closing Remarks** | **Dan Milam**, Vice President, Global Engagement, **SCRS** |